.avif)
ANA Therapeutics was a privately held biotechnology company developing ANA-001, a proprietary oral capsule formulation of niclosamide for the treatment of COVID-19. The company was acquired by NeuroBo Pharmaceuticals in December 2020, bringing a Phase 2/3 clinical program for moderate to severe COVID-19. Niclosamide, the active ingredient, has a 50-year safety history as an anti-parasitic and demonstrated antiviral and anti-inflammatory activity against SARS-CoV-2 in preclinical studies. Note: this company does not have a standalone public website; information is sourced from the NeuroBo Pharmaceuticals acquisition press release.
.svg)
